New 2025 Data Sheds Light on 340B Activity in Georgia
Pioneer Institute has released updated #340B state fact sheets for 2025
The Pioneer Institute has released updated 340B State Fact Sheets for 2025, offering a detailed look into how the 340B Drug Pricing Program is operating in each state—including Georgia. The findings raise key questions about equity, oversight, and impact on low-income communities.
In Georgia:
- 30% of the state’s 340B contract pharmacies are located outside of Georgia, including some as far away as Hawaii.
- 43% of contract pharmacies intended to serve low-income Georgians are actually located in affluent neighborhoods.
- Some hospitals, such as Northside Hospital and AU Medical Center, operate dozens of contract pharmacies—many out of state—while others serve patients effectively with far fewer.
- PBM-owned and chain pharmacies dominate the list of top 340B contract pharmacies in Georgia.
- Despite these concerns, Georgia 340B hospitals reported above-average charity care: 4.92% of operating expenses compared to the national average of 2.15%.
The data also explores:
- Which hospitals have the most (and most out-of-state) contract pharmacies
- How charity care levels vary between insured and uninsured patients
- The correlation between hospital wealth and charitable contributions
➡️ View Georgia’s full 2025 fact sheet and explore national comparisons: https://pioneerinstitute.org/340babuse/340b-state-fact-sheets
As policymakers continue to examine the effectiveness and transparency of the 340B program, this report highlights the importance of tracking how resources intended for underserved populations are actually being deployed.
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.
Georgia Life Sciences’ CEO, Maria Thacker Goethe shares her perspective on the value of Georgia’s research universities in this month’s issue of Georgia Trend. “Georgia research institutions have felt a very significant impact from the federal rollbacks, specifically in NIH and NSF funding. Thacker Goethe’s message about the impact of research cuts is simple: Disruption shatters the foundational trust researchers have in grant continuity….” To read the full article, click here .
